|
U.S. Centers for Disease Control and Prevention
• Medical News
U.S. Food and Drug Administration Approves Cangene's Anti-Hepatitis B Product, Winnipeg Company Says
January 31, 2006 On Monday, Cangene Corp. said the Food and Drug Administration has approved its HepaGam B treatment for hepatitis B virus (HBV) for sale in the United States. The drug has been approved for treatment of acute exposure to blood containing HBV surface antigen, perinatal exposure of infants born to infected mothers, and sexual and household exposure to infected persons. Winnipeg-based Cangene expects HepaGam B will be launched within a few months and be distributed by Apotex Corp. Back to other news for January 31, 2006 Canadian Press 01.30.06 This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. |
|
